Brought to you by 
BMS, Merck develop muraglitazar for diabetes: terminated
23 Feb 2006
Executive Summary
Bristol-Myers Squibb and Merck & Co. will jointly develop and commercialize Bristol's muraglitazar, a dual peroxisome proliferator-activated receptor (PPAR) agonist that is in Phase III clinical trials to manage Type II diabetes and the lipid abnormalities often associated with the disease, especially high triglyceride and low HDL levels.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS, Merck develop muraglitazar for diabetes: terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice